TITLE:
Experimental Therapeutic Trial of an Antibody against the Cell Adhesion Molecule Gicerin for Lymphomas Using a Murine Cell Line
AUTHORS:
Yasuhiro Tsukamoto, Yukiko Miyagawa, Osamu Maeda
KEYWORDS:
Gicerin, Cell Adhesion Molecule, Lymphoma, Mouse
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.9 No.10,
October
15,
2018
ABSTRACT: Chemotherapy,
occasionally combined with radiotherapy, is a
major method for treating lymphoma but frequently produces side-effects
in patients. Thus, novel therapeutics should be developed as an alternative the
chemotherapy in lymphoma patients. Although
the cell adhesion molecule gicerins are almost entirely absent in most mature
tissues, except for muscle and endothelial cells, various neoplastic cells
strongly express gicerin in their cell membranes. This suggests the
potential function of gicerin in the progression of tumors, including tumor
growth, invasion and metastasis to distant organs from primary sites. In the
present study, we assessed therapeutic effects of anti-gicerin antibodies on the murine lymphoma
cell line YAC1. Gicerin was found to be expressed in the cell membrane of YAC1
cells and promoted the cell adhesion activity of the YAC1 cells on HUVECs, an
endothelial cell line. In addition, YAC1 cells were implanted sub-cutaneously in mice
in order to examine the therapeutic effects of anti-gicerin antibodies on
lymphoma progression in vivo. The anti-gicerin antibodies suppressed and reduced the lymphoma tumor
growth in the mice, whereas the growth of tumor mass was not inhibited by
pre-immune IgG administrations. YAC1 cells were also implanted intravenously in
mice in order to examine the effects of anti-gicerin antibodies on the
pulmonary metastasis of lymphoma cells. The metastasis of the YAC1 cells to the
lungs was inhibited by the injection of anti-gicerin antibodies. These findings
indicate that anti-gicerin antibodies inhibit the progression of
prednisolone-resistant lymphoma, making
this a promising novel therapeutic method for treating refractory lymphoma
cases.